bimekizumab: Clinical Trials

6 completed, 1 recruiting, 1 terminated. 8 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	8	Completed 6, Recruiting 1, Terminated 1

Follow bimekizumab: new trials by email Literature Review of bimekizumab trials Research Report on bimekizumab

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis	Phase 1	Recruiting	UCB Biopharma SRL	20	2025-11-05	2026-09-18
A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants bimekizumab - Healthy Study Participants	Phase 1	Completed	UCB Biopharma SRL	121	2022-03-17	2025-04-10
A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants Bimekizumab - Healthy Study Participants	Phase 1	Terminated	UCB Biopharma SRL	71	2020-02-12	2025-04-10
A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects Bimekizumab - Healthy Volunteers	Phase 1	Completed	UCB Biopharma S.P.R.L.	56	2019-04-02	2020-09-17
A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants Bimekizumab - Healthy Volunteers	Phase 1	Completed	UCB Biopharma S.P.R.L.	189	2018-10-15	2020-06-16
A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects Bimekizumab - Healthy Volunteers	Phase 1	Completed	UCB Celltech	12	2016-03-04	2021-08-31
Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis UCB4940 40 mg, UCB4940 80 mg, UCB4940 160 mg - Psoriatic Arthritis	Phase 1	Completed	UCB Celltech	53	2014-05-01	2015-09-01
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis UCB4940, Placebo - Mild to Moderate Psoriasis	Phase 1	Completed	UCB Celltech	39	2012-11-01	2015-08-20

Conditions studied

Arthritis, Psoriatic (2)  ·  Axial Spondyloarthritis (1)  ·  Hidradenitis Suppurativa (1)  ·  Psoriasis (1)

Sponsors

UCB Biopharma SRL (3)  ·  UCB Celltech (3)  ·  UCB Biopharma S.P.R.L. (2)

Countries

Germany (4)  ·  United States (4)  ·  United Kingdom (3)  ·  Bulgaria (1)  ·  Canada (1)  ·  Moldova (1)  ·  Spain (1)  ·  Switzerland (1)

Results publications

PMID 27859546, PMID 29275332

NIH funding

2017 (1), 2019 (1)